Overview

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Status:
Completed
Trial end date:
2014-11-25
Target enrollment:
Participant gender:
Summary
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Europe Ltd.
Treatments:
Mirabegron
Solifenacin Succinate